FDA Strong Drug Ties-Less Monitoring – UK MHRA Mon, 6 Dec 2004 A front page article in The New York Times provides a historical perspective to the shift in FDA’s focus (in 1992) from watchdog safeguarding the public against hazardous drugs, food and medical devices, to its current role as…
Bush Plans to Screen Whole US Population for Mental Illness – BMJ Thu, 24 Jun 2004 A second article in the British Medical Journal discloses additional evidence uncovered by Allen Jones, the whistle blower from the Pennsylvania Inspector General’s Office. The first BMJ article focused on the Texas Medication Algorithm…
Screening for Mental Illness–A Diabolical, Profit-Enhancing Experiment Fri, 22 Oct 2004 Concerned citizen groups are joining our effort to stop the government from implementing a sweeping recommendation for lifetime screening for mental illness. If implemented, the first to be screened for hidden mental illness are America’s 52 million school children…
To view AHRP news and infomails from 2006, please visit our new site. Infomails Subscribe to AHRP’s infomails At FDA, Graham is still the whistle-blower Loss of Trust: Big Drug Makers See Sales Decline With Their Image War hero’s death in clinical trial follows years of FDA neglect European perspective:…
Infomail 2004 News Stories on Human Research Protection and Commentary by Vera Hassner Sharav Dec 31: FDA to review “missing” drug company documents Dec 30: Family of Woman Killed by AIDS Drug Test Sues Doctors, Manufacturer Dec 30: Doctors, Too, Ask: Is This Drug Right? Dec 29: Bill would shield…
Fewer Kids Prescribed Drugs for Depression – WashPost Wed, 2 Feb 2005 A report by Medco revealing a decline in SSRI prescriptions for children is giving drug industry stakeholders nightmares about the cash flow. The Washington Post reports "medical groups such as the American Psychiatric Association and the American Academy…
Pfizer Admits Guilt in Promotion of Neurontin–Agrees to Pay $430 Million Sun, 16 May 2004 A lawsuit initiated by Dr. David Franklin, a whistleblower, has been settled: Pfizer pleaded guilty to criminal fraud in the promotion of Neurontin, and agreed to pay $430 million. This case is but an example…
4 compelling reasons against Mental Health Parity Fri, 12 Sep 2003 Compelling reasons NOT to approve insurance parity for mental health services come from the following recent reports suggesting that mental health services and treatments have often done more damage than good. Until psychiatry and mental health service providers develop…
GlascoSmithKline PAXIL Warning letter to Healthcare Professionals Thu, 19 Jun 2003 On June 10 the British government disapproved a license the widely popular, SSRI antidepressant, Seroxat (PAXIL), for use in children and adolescents after a committee examined the data from 9 clinical trials. The British Medicine and Healthcare Products Regulatory…
FATAL FLAW Efforts to Overturn SSRI Black Box warning before it has even been implemented Date: Mon, 24 Jan 2005 Even as the Black Box Suicidality Warning on SSRI antidepressant labels have not even been implemented, aggressive efforts are underway by a powerful consortium of medical-pharmaceuticaql self-interest groups – among…
Dr. Kramer – All Things They Taught Us That Were Wrong in Psychiatry Thu, 15 Sep 2005 In a 2004 column, a psychiatrist who engages in “myth busting” inadvertently confirms that psychiatry is given to prescribing mood swings. He acknowledges that sometimes effective treatments are dropped (benzodiazepines) for new ones…
Additional information as of late Wed Oct 19: Although I was assured that attendance for a presentation by Dr. David Healy (at Columbia University School of Public Health on Oct. 20 at 12:30) would be open to the public, a problem seems to have emerged after an AHRP Infomail about…
